Tirzepatide is a novel medication that is FDA approved for the treatment of type 2 diabetes mellitus. It is composed of 39 amino acids and is an analog of the gastric inhibitory polypeptide. Given its potent weight loss properties, Tirzepatide can be used for obesity treatment. It works as a dual GLP-1 agonist and GIP agonist to maximize similar benefits that are seen with GLP-1 medications such as Semaglutide, and is given as a once-a-week subcutaneous injectable. The FDA approved Tirzepatide in May 2022. The main difference between Semaglutide and Tirzepatide is that Tirzepatide activates two hormone receptors – GLP-1 and GIP – while Semaglutide only activates GLP-1. This may give Tirzepatide a greater effect on blood glucose, appetite, and weight loss.
Our services do not take the place of your physician’s advice. These statements have not been evaluated by the FDA. As with any new treatment, please consult your physician if you have any concerns or to see if this is right for you.
Free call 24/7
+1-866-4 CORE iV